ImmunityBio Stock Quote IBRX - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

7.60

Bid

7.29

Ask

7.75

Volume

40,280,221

4.9201 Day's Range 7.74

1.25 52 Week Range 7.74

Market Cap

21.694B

Previous Close

5.11

Open

5.11

Last Trade

335

7.6

(formt)

Last Trade Time

Financial Volume

$ 250,337,735

VWAP

6.2149

Average Volume (3m)

4,910,123

Shares Outstanding

667,705,368

Dividend Yield

PE Ratio

-37.20

Earnings Per Share (EPS)

-0.87

Revenue

622k

Net Profit

-583.2M

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cel... ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.immunitybio.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

ImmunityBio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IBRX. The last closing price for ImmunityBio was $5.11. Over the last year, ImmunityBio shares have traded in a share price range of $ 1.25 to $ 7.74.

ImmunityBio currently has 667,705,368 shares outstanding. The market capitalization of ImmunityBio is $21.69 billion. ImmunityBio has a price to earnings ratio (PE ratio) of -37.20.

Overall Flow

Bullish

Net Premium

286k

Calls / Puts

162.96%

Buys / Sells

78.38%

OTM / ITM

47.92%

Sweeps Ratio

0.01%

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer...

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Designated an FDA Breakthrough Therapy, the novel immunotherapy ANKTIVA activates the body’s natural killer (NK) and killer T-cell immune system to attack tumor cells Therapy stimulates memory T...

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the recent publication of preclinical data in the online issue of Science, First Release indicating that...

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

All participants in the Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well tolerated N-803 is being studied in three...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

The first 20 participants have been enrolled in an important national, multicenter trial to test whether ImmunityBio’s Nant Cancer Vaccine (NCV) comprising a tri-valent Adenovirus (Tri-Ad5) in...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	2.69	54.7861507128	4.91	7.74	4.79	11230121	5.27598035	CS
4	2.25	42.0560747664	5.35	7.74	4.73	5856676	5.38748739	CS
12	4.07	115.297450425	3.53	7.74	3.37	4910123	5.04960958	CS
26	5.91	349.704142012	1.69	7.74	1.62	5330080	4.21119027	CS
52	5.23	220.675105485	2.37	7.74	1.25	4526567	3.59984779	CS
156	-11.14	-59.4450373533	18.74	19.72	1.21	2723822	4.45572605	CS
260	-28.95	-79.2065663475	36.55	40.834	1.21	2663645	4.86841427	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.3254 (82.86%)	70.82M
IBRXImmunityBio Inc	$ 7.35 (43.84%)	40.28M
AGENAgenus Inc	$ 11.685 (40.78%)	3.37M
ULHUniversal Logistics Holdings Inc	$ 45.63 (38.74%)	484.22k
NIVFNewGenIvf Group Ltd	$ 1.77 (36.15%)	57.78M
MFImF International Ltd	$ 2.3153 (-77.82%)	21.23M
NWGLNature Wood Group Ltd	$ 5.05 (-70.03%)	2.48M
ICLKiClick Interactive Asia Group Ltd	$ 1.21 (-52.17%)	719.95k
NUWENewellis Inc	$ 0.1695 (-41.35%)	18.46M
SGBXSafe and Green Holdings Corporation	$ 0.1469 (-32.92%)	8.39M
PEGYPineapple Energy Inc	$ 0.065499 (26.20%)	325.57M
SQQQProShares UltraPro Short QQQ	$ 11.43 (-4.75%)	137.28M
INTCIntel Corporation	$ 31.88 (-9.20%)	119.84M
TSLATesla Inc	$ 168.29 (-1.11%)	109.84M
SOFISoFi Technologies Inc	$ 7.87 (3.69%)	88.63M